GlaxoSmithKline plc / Domantis Limited

Inflammatory & Respiratory Diseases (RA, asthma, COPD)

Disease Overview

Rheumatoid arthritis, asthma and COPD are chronic immune/inflammatory conditions in which dysregulated cytokine signaling — TNF, IL-1, IL-4, IL-13, IL-6 — drives tissue damage and morbidity. Conventional monoclonal antibodies have transformed care but remain large, injection-only proteins with manufacturing complexity and limited tissue penetration, leaving an opening for next-generation antibody formats.

Competitive Landscape

By 2006 the immunology biologic market was anchored by AbbVie/Eisai's Humira (adalimumab), Amgen/Wyeth's Enbrel (etanercept), and J&J's Remicade (infliximab) for RA; for asthma Genentech/Novartis's Xolair (omalizumab) had carved out severe allergic disease, and COPD relied largely on inhaled long-acting bronchodilators and ICS combinations (Advair, Spiriva). Domantis's domain antibody (dAb) platform offered a structurally differentiated approach: ~12 kDa single-domain fragments derived from human VH or VL chains that, per Mike Owen of GSK, "pioneered the extension of antibody therapies to potentially far wider applications than has been possible with conventional monoclonal antibodies". Programs included an anti-TNF dAb, an inhaled lung-directed anti-inflammatory for COPD, a dual IL-4/IL-13 dAb for asthma, and IL-1 pathway dAbs for RA. Strategically the deal vaulted GSK back into the antibody race after years of dependence on small molecules; commercially it underdelivered — no Domantis-originated dAb reached approval, and GSK's Big Bio winners (Nucala, Benlysta) came from other programs. Domain-antibody and nanobody competition consolidated around Sanofi's 2018 acquisition of Ablynx ($4.8B), which had won the 2014 European patent dispute against Domantis.